Drugs / Bindarit
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01269242 | Jan 2009 → Jan 2011 | coronary restenosis | Angelini Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01109212 | Mar 2007 → Nov 2008 | diabetic kidney disease | Angelini Pharma | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bindarit | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01269242 ↗ |
| Known as | AF 2838 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107549 ↗ |
| Action | Inhibit | “a selective inhibitor of MCP-1 and other members of monocyte chemotactic protein subfamily of CC inflammatory chemokines (MCP-3/CCL7, MCP-2/CCL8), such as bindarit” NCT01269242 ↗ |
| Modality | Small molecule | — CHEMBL2107549 ↗ |
| Target | CCL7 | “a selective inhibitor of MCP-1 and other members of monocyte chemotactic protein subfamily of CC inflammatory chemokines (MCP-3/CCL7, MCP-2/CCL8), such as bindarit” NCT01269242 ↗ |
| Target | CCL8 | “a selective inhibitor of MCP-1 and other members of monocyte chemotactic protein subfamily of CC inflammatory chemokines (MCP-3/CCL7, MCP-2/CCL8), such as bindarit” NCT01269242 ↗ |